PrimeRFP SCOUT · Federal Contract Recompete Brief

W81XWH20C0137 — FURTHER DEVELOPMENT OF ETVAX, A VACCINE AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC).

FURTHER DEVELOPMENT OF ETVAX, A VACCINE AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC). is a federal NONE award for Department of Defense (DOD) held by SCANDINAVIAN BIOPHARMA HOLDING AB. Estimated value $51.7M ($31.3M obligated). Current period of performance ends Sep 30, 2028. Last award drew 1 bidder.

$51.7M
Estimated Value
$31.3M
Obligated
Sep 30, 2028
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

SCANDINAVIAN BIOPHARMA HOLDING AB holds $21.8M across 1 federal awards, concentrated at Department of Defense (DOD). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 30, 2028 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract numberW81XWH20C0137
AgencyDepartment of Defense (DOD)
IncumbentSCANDINAVIAN BIOPHARMA HOLDING AB
UEIZKASUJ7ZZC98
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCQ517
PoP end (current)Sep 30, 2028
Obligated$31.3M

FURTHER DEVELOPMENT OF ETVAX, A VACCINE AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC).

Recompete timing

Public
Expiring in 775 days

Current PoP ends Sep 30, 2028 (775 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Mar 30, 2027.

Watch this contract — one email →

Incumbent footprint

Public record

SCANDINAVIAN BIOPHARMA HOLDING AB$21.8M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Defense (DOD)
Department of Defense (DOD)$21.8M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open SCANDINAVIAN BIOPHARMA HOLDING AB’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract W81XWH20C0137?

W81XWH20C0137 (FURTHER DEVELOPMENT OF ETVAX, A VACCINE AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC).) is a Department of Defense (DOD) award with an estimated value of $51.7M, currently held by SCANDINAVIAN BIOPHARMA HOLDING AB. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on W81XWH20C0137?

SCANDINAVIAN BIOPHARMA HOLDING AB is the incumbent with $21.8M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2028.

When does W81XWH20C0137 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W81XWH20C0137